{
    "clinical_study": {
        "@rank": "63565", 
        "arm_group": {
            "arm_group_label": "Synthetic Surfactant", 
            "arm_group_type": "Experimental", 
            "description": "Cohort Design"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to investigate the safety and tolerability of intratracheal\n      administration of two different single doses of CHF 5633 in preterm neonates with RDS in\n      terms of adverse events, adverse drug reactions, hematology and biochemistry values, the\n      incidence of major neonatal morbidities including bronchopulmonary dysplasia (BPD) and\n      mortality."
        }, 
        "brief_title": "First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Distress Syndrome in Premature Infants", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be a multicentre, open-label, single escalating dose, per-cohort design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent obtained by parents/legal representative (according to local\n             regulation) prior to any study-related procedures\n\n          -  Inborn and outborn, preterm neonates of either sex with a gestational age of 27 weeks\n             up to 33 weeks+6\n\n          -  Clinical and radiological findings typical of RDS\n\n          -  Age on admission to the study < 24 hours from birth\n\n          -  Requirement of endotracheal intubation for surfactant administration\n\n          -  Fraction of inspired oxygen (FiO2) > 0.35 to maintain SpO2 between 90-95 %\n\n          -  Documentation of normal cranial ultrasound scan\n\n        Exclusion Criteria:\n\n          -  Use of surfactant prior to study entry and need for intratracheal administration of\n             any other treatment (e.g. nitric oxide)\n\n          -  Known genetic or chromosomal disorders, major congenital anomalies (cardiac\n             malformations, myelomeningocele etc)\n\n          -  Maternal drug abuse (heroin, methadone, methamphetamine, or cocaine) or significant\n             alcohol consumption during pregnancy\n\n          -  Clinical chorioamnionitis (Appendix III)\n\n          -  Strong suspicion of congenital pneumonia/infection, sepsis\n\n          -  Evidence of severe birth asphyxia or a 5 minutes Apgar score less / equal 3\n\n          -  Presence of air leaks prior to study entry\n\n          -  Neonatal seizures prior to study entry\n\n          -  Mothers with prolonged rupture of the membranes (> 3 weeks duration)\n\n          -  Any condition that, in the opinion of the Investigator, would place the neonate at\n             undue risk\n\n          -  Participation in another clinical trial of any placebo, drug or biological substance\n             conducted under the provisions of a protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "34 Weeks", 
            "minimum_age": "27 Weeks"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651637", 
            "org_study_id": "CCD-1011-PR-0059"
        }, 
        "intervention": {
            "arm_group_label": "Synthetic Surfactant", 
            "description": "CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration", 
            "intervention_name": "synthetic surfactant (CHF5633)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pulmonary Surfactants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Respiratory Distress syndrome", 
            "Complications of prematurity"
        ], 
        "lastchanged_date": "January 30, 2013", 
        "location": {
            "contact": {
                "email": "mark.turner@liverpool.ac.uk", 
                "last_name": "Mark Turner, MD", 
                "phone": "(0) 151-702-4101", 
                "phone_ext": "+44"
            }, 
            "facility": {
                "address": {
                    "city": "Liverpool", 
                    "country": "United Kingdom"
                }, 
                "name": "Liverpool Women's Hospital Neonatal Unit Liverpool Women's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome", 
        "overall_contact": {
            "email": "g.varoli@chiesi.com", 
            "last_name": "Guido Varoli", 
            "phone": "+390521279718"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e4ts-Kinderklinik W\u00fcrzburg (Germany)", 
            "last_name": "Christian Speer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Monitoring of adverse events following CHF5633 administration", 
            "safety_issue": "Yes", 
            "time_frame": "For duration of hospital stay (expected average of 9 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "CHF 5633 efficacy profile (oxygenation , ventilatory requirements and need for rescue surfactant treatment),systemic absorption and immunogenicity assesment", 
            "safety_issue": "No", 
            "time_frame": "At min 30, at hrs 1, 3, 6, 12, 24, at days 2, 3, 7 and at days 10, 28, at 36 weeks pma post dosing for ventilatory requirements, at pre-dose and 3 hrs and 24 hrs post dosing for systemic absorption and at 8 wks after administration for immunogenicity"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}